Peptides in the treatment of AIDS

Current Opinion in Structural Biology

Volumn 19, Issue 4, 2009, Pages 473-482

  Naider, Fred ^a   Anglister, Jacob ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; SIFUVIRTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL FUSION; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INHIBITION KINETICS; LYMPHOCYTE; MACROPHAGE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; ROENTGEN SPECTROSCOPY; TARGET CELL; VIRUS ENTRY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANIMALS; DRUG DESIGN; HIV FUSION INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; VIRAL ENVELOPE PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 69249116120     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sbi.2009.07.003     Document Type: Review

References (52)

1. Liu S., Wu S., and Jiang S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des 13 (2007) 143-162. Comprehensive review of the design of HIV-1 inhibitors targeting gp41 (133 references).
2. Chan D.C., Fass D., Berger J.M., and Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 (1997) 263-273. Determination of the crystal structure of the gp41 core formed using synthetic peptides.
3. Tan K., Liu J., Wang J., Shen S., and Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94 (1997) 12303-12308
4. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., and Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 (1997) 426-430. Description of the crystal structure of the gp41 core using crystals formed from biosynthetic and synthetic peptides.
5. Chan D.C., and Kim P.S. HIV entry and its inhibition. Cell 93 (1998) 681-684
6. Jiang S., Lin K., Strick N., and Neurath A.R. HIV-1 inhibition by a peptide. Nature 365 (1993) 113
7. Wild C., Oas T., McDanal C., Bolognesi D., and Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89 (1992) 10537-10541
8. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., and Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91 (1994) 9770-9774
9. Chan D.C., Chutkowski C.T., and Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 95 (1998) 15613-15617. Identification of hydrophobic pocket in the six-helix bundle formed by gp41 N-HR and C-HR. This pocket is critical in the design of inhibitory peptides that target it.
10. Otaka A., Nakamura M., Nameki D., Kodama E., Uchiyama S., Nakamura S., Nakano H., Tamamura H., Kobayashi Y., Matsuoka M., et al. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl 41 (2002) 2937-2940. Design of water-soluble C34 analogs based on helical conformation and consideration of exposed and buried faces of the C-peptide. Designed peptides have increased solubility and are helical by CD.
11. Lu M., and Kim P.S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 15 (1997) 465-471
12. Dwyer J.J., Wilson K.L., Davison D.K., Freel S.A., Seedorff J.E., Wring S.A., Tvermoes N.A., Matthews T.J., Greenberg M.L., and Delmedico M.K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A 104 (2007) 12772-12777. Design of improved fusion peptides using conformation-based analogs that have increased helicity. The analogs were effective against T-20 resistant HIV-1 strains. Paper demonstrates that the topology of the interaction can be mimicked by peptides with major differences in sequence compared to the native C-HR peptide.
13. Nishikawa H., Nakamura S., Kodama E., Ito S., Kajiwara K., Izumi K., Sakagami Y., Oishi S., Ohkubo T., Kobayashi Y., et al. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int J Biochem Cell Biol 41 (2009) 891-899. Conformation-directed design of Fuzeon-like peptide analogs based on electrostatic interactions. Paper has crystal structure showing that these highly modified gp41 surrogates form a crystal highly similar to that formed by native gp41 peptides.
14. He Y., Xiao Y., Song H., Liang Q., Ju D., Chen X., Lu H., Jing W., Jiang S., and Zhang L. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283 (2008) 11126-11134
15. Naito T., Izumi K., Kodama E., Sakagami Y., Kajiwara K., Nishikawa H., Watanabe K., Sarafianos S.G., Oishi S., Fujii N., et al. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother 53 (2009) 1013-1018
16. Liu S., Jing W., Cheung B., Lu H., Sun J., Yan X., Niu J., Farmar J., Wu S., and Jiang S. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem 282 (2007) 9612-9620. This study provides convincing evidence that the C34 and T-20 inhibitors inhibit fusion via different molecular interactions.
17. Yuan W., Craig S., Si Z., Farzan M., and Sodroski J. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol 78 (2004) 5448-5457
18. Alam S.M., Paleos C.A., Liao H.X., Scearce R., Robinson J., and Haynes B.F. An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. AIDS Res Hum Retroviruses 20 (2004) 836-845
19. Greenberg M.L., and Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54 (2004) 333-340
20. Mo H., Konstantinidis A.K., Stewart K.D., Dekhtyar T., Ng T., Swift K., Matayoshi E.D., Kati W., Kohlbrenner W., and Molla A. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. Virology 329 (2004) 319-327. Systematic molecular biology and modeling analysis of the interactions that occur in the deep hydrophobic pocket of the gp41 coiled-coil core.
21. Chang D.K., and Hsu C.S. Biophysical evidence of two docking sites of the carboxyl heptad repeat region within the amino heptad repeat region of gp41 of human immunodeficiency virus type 1. Antiviral Res 74 (2007) 51-58. Evidence for bi-modal binding of a C34 like peptide to the N-HR region of gp41 based on scanning analysis.
22. Qi Z., Shi W., Xue N., Pan C., Jing W., Liu K., and Jiang S. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J Biol Chem 283 (2008) 30376-30384. Systematic analysis of the role of PBD and LBD domains on fusion peptide inhibitors.
23. Noah E., Biron Z., Naider F., Arshava B., and Anglister J. The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N′ peptide. Biochemistry 47 (2008) 6782-6792. Demonstration that T-20 forms a stable 6-HB with a properly matched N-HR peptide of gp41. Study has implications on the mechanism of action of T-20. It also indicates that conclusions pertaining to 6-HB formation should consider the matching of the C-HR and N-HR regions.
24. Lorizate M., de la Arada I., Huarte N., Sanchez-Martinez S., de la Torre B.G., Andreu D., Arrondo J.L., and Nieva J.L. Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence. Biochemistry 45 (2006) 14337-14346
25. Bellamy-McIntyre A.K., Lay C.S., Baar S., Maerz A.L., Talbo G.H., Drummer H.E., and Poumbourios P. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem 282 (2007) 23104-23116
26. Liu S., Lu H., Niu J., Xu Y., Wu S., and Jiang S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 280 (2005) 11259-11273
27. Wexler-Cohen Y., Johnson B.T., Puri A., Blumenthal R., and Shai Y. Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem 281 (2006) 9005-9010. Insertion of d residues into T-20 alters the biological activity and interaction profile with an N-HR peptide.
28. He Y., Cheng J., Lu H., Li J., Hu J., Qi Z., Liu Z., Jiang S., and Dai Q. Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci U S A 105 (2008) 16332-16337. Incorporation of residues upstream of the pocket-binding domain of C-HR peptides increases 6-HB stability and results in pm inhibition constants. Designed peptide has a broad range of anti-HIV-1 potency and is effective against peptides resistant to T-20 and C34.
29. He Y., Cheng J., Li J., Qi Z., Lu H., Dong M., Jiang S., and Dai Q. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J Virol 82 (2008) 6349-6358
30. Caffrey M., Cai M., Kaufman J., Stahl S.J., Wingfield P.T., Covell D.G., Gronenborn A.M., and Clore G.M. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J 17 (1998) 4572-4584
31. Champagne K., Shishido A., and Root M.J. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem 284 (2009) 3619-3627. Use of a redesigned five-helix to investigate the mode of binding of T-20.
32. Biron Z., Khare S., Quadt S.R., Hayek Y., Naider F., and Anglister J. The 2F5 epitope is helical in the HIV-1 entry inhibitor T-20. Biochemistry 44 (2005) 13602-13611. Use of heteronuclear labeling to determine the NMR structure of an extended T-20 peptide in water. Study concludes that significant portions of T-20 assume a helical structure in water. This differs from the conclusions of CD analysis on this peptide.
33. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., and Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78 (2004) 10724-10737
34. Sun Z.Y., Oh K.J., Kim M., Yu J., Brusic V., Song L., Qiao Z., Wang J.H., Wagner G., and Reinherz E.L. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28 (2008) 52-63. NMR and EPR investigation of gp41 peptide bound to micelles and 4E10 antibody. Provides insights into the membrane bound structure of gp41 peptides and to the mechanism of binding of a broadly neutralizing Ab to gp41.
35. Wexler-Cohen Y., and Shai Y. Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J 21 (2007) 3677-3684. Development of C-HR-fatty acid conjugates that have high anti HIV-1 potency. First demonstration that the peptide-peptide interaction in the formation of the 6-HB can be mimicked by a fatty acid. This has important implications for design of a peptidomimetic entry inhibitor.
36. 50 values and were active against a panel of primary isolates and had dramatically increased serum lifetimes.
37. Schwyzer R. Peptide-membrane interactions and a new principle in quantitative structure-activity relationships. Biopolymers 31 (1991) 785-792
38. Root M.J., Kay M.S., and Kim P.S. Protein design of an HIV-1 entry inhibitor. Science 291 (2001) 884-888. Design of 5-helix a C-HR-directed HIV-1 fusion inhibitor composed of a five-helix bundle.
39. Eckert D.M., and Kim P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A 98 (2001) 11187-11192. The use of N-HR peptides as fusion inhibitors. Paper discusses increasing the stability of the trimeric core by attachment of soluble leucine zipper sequences. Activity of the peptides increases 1000-fold.
40. Louis J.M., Bewley C.A., and Clore G.M. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 276 (2001) 29485-29489
41. Bianchi E., Finotto M., Ingallinella P., Hrin R., Carella A.V., Hou X.S., Schleif W.A., Miller M.D., Geleziunas R., and Pessi A. Covalent stabilization of coiled coils of the HIV gp41N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A 102 (2005) 12903-12908. Disulfide linked coiled-coils based on a fusion of the gp41 N-HR region and a soluble coiled-coil forming sequence exhibited broad antiviral activity and pm inhibition constants.
42. Dwyer J.J., Wilson K.L., Martin K., Seedorff J.E., Hasan A., Medinas R.J., Davison D.K., Feese M.D., Richter H.T., Kim H., et al. Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency. Protein Sci 17 (2008) 633-643. Engineering of isolated N-peptides that form a soluble trimeric coiled-coil. Study shows viral inhibition is related to the formation of trimer and not necessarily to stability of the trimeric coiled-coil.
43. Hrin R., Montgomery D.L., Wang F., Condra J.H., An Z., Strohl W.R., Bianchi E., Pessi A., Joyce J.G., and Wang Y.J. Short communication: in vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Hum Retroviruses 24 (2008) 1537-1544. Demonstration of synergy between N-HR and C-HR-based fusion inhibitors.
44. Eckert D.M., Malashkevich V.N., Hong L.H., Carr P.A., and Kim P.S. Inhibiting HIV-1 entry: discovery of d-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99 (1999) 103-115. Use of phage display and a structure-based hook to identify d-peptide fusion inhibitors.
45. Welch B.D., VanDemark A.P., Heroux A., Hill C.P., and Kay M.S. Potent d-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A 104 (2007) 16828-16833. Optimization of small all d-fusion inhibitors with increased avidity and anti-HIV-1 potency. Study shows avidity is an important aspect of obtaining inhibitors with extremely high affinities. However, must take into account kinetic factors as well when designing antiviral entry inhibitors.
46. Gaston F., Granados G.C., Madurga S., Rabanal F., Lakhdar-Ghazal F., Giralt E., and Bahraoui E. Development and characterization of peptidic fusion inhibitors derived from HIV-1 gp41 with partial d-amino acid substitutions. ChemMedChem 4 (2009) 570-581
47. Steger H.K., and Root M.J. Kinetic dependence to HIV-1 entry inhibition. J Biol Chem 281 (2006) 25813-25821. Detailed analysis shows that there is a better correlation between inhibitory potency and association constants of inhibitors than there is with their binding affinities to 5-helix. This paper is important for the design of inhibitors as it shows that steric factors which influence binding kinetics may play a role in the efficacy of the inhibitor.
48. Eckert D.M., Shi Y., Kim S., Welch B.D., Kang E., Poff E.S., and Kay M.S. Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci 17 (2008) 2091-2100. The gp41 prehairpin trimer is sterically blocked from antibodies and large C-peptide inhibitors and the nature of this steric defense is asymmetric with respect to the viral and target cell membranes.
49. Stoddart C.A., Nault G., Galkina S.A., Thibaudeau K., Bakis P., Bousquet-Gagnon N., Robitaille M., Bellomo M., Paradis V., Liscourt P., et al. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem 283 (2008) 34045-34052
50. Strockbine B., and Rizzo R.C. Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: quantitative correlation with experiment. Proteins 67 (2007) 630-642. MD calculations of affinities of C-HR peptides to a conserved hydrophobic-binding pocket correlated well with experimental-binding constants.
51. Liu K., Lu H., Hou L., Qi Z., Teixeira C., Barbault F., Fan B.T., Liu S., Jiang S., and Xie L. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem 51 (2008) 7843-7854. Recent update on small molecule fusion inhibitors. Most lead compounds have micromolar inhibition constants.
52. Balogh E., Wu D., Zhou G., and Gochin M. NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41. J Am Chem Soc 131 (2009) 2821-2823. A novel NMR method based on paramagnetic relaxation effects to determine structure of small molecule inhibitors bound to the hydrophobic pocket of gp41.